Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin

References

• Look AHEAD Research GroupWingRRBolinPCardiovascular effects of intensive lifestyle intervention in type 2 diabetesN Engl J Med2013369214515423796131
   PubMed Web of Science ®Google Scholar
• KingPPeacockIDonnellyRThe UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetesBr J Clin Pharmacol199948564364810594464
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) [webpage on the Internet]Guidance for Industry Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdfAccessed February 14, 2016
   Google Scholar
• HirshbergBRazIImpact of the U.S. food and drug administration cardiovascular assessment requirements on the development of novel antidiabetes drugsDiabetes Care201134suppl 2S101S10621525438
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trialLancet200536694931279128916214598
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• WrightEMHirayamaBALooDFActive sugar transport in health and diseaseJ Intern Med20072611324317222166
   PubMed Web of Science ®Google Scholar
• TurkEMartinMGWrightEMStructure of the human Na+/glucose cotransporter gene SGLT1J Biol Chem19942692115204152098195156
   PubMed Web of Science ®Google Scholar
• FreitasHSAnheGFMeloKFNa(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activityEndocrinology2008149271772417962340
   PubMed Web of Science ®Google Scholar
• RahmouneHThompsonPWWardJMSmithCDHongGBrownJGlucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetesDiabetes200554123427343416306358
   PubMed Web of Science ®Google Scholar
• KomoroskiBVachharajaniNBoultonDDapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjectsClin Pharmacol Ther200985552052619129748
   PubMed Web of Science ®Google Scholar
• HeiseTSeewaldt-BeckerEMachaSSafety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetesDiabetes Obes Metab201315761362123356556
   PubMed Web of Science ®Google Scholar
• ShaSDevineniDGhoshACanagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes Obes Metab201113766967221457428
   PubMed Web of Science ®Google Scholar
• WashburnWNPoucherSMDifferentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitusExpert Opin Investig Drugs2013224463486
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMANortonLDeFronzoRARenal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusAm J Physiol Renal Physiol201530911F889F90026354881
   PubMed Web of Science ®Google Scholar
• ThomsonSCRiegTMiracleCAcute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic ratAm J Physiol Regul Integr Comp Physiol20123021R75R8321940401
   PubMed Web of Science ®Google Scholar
• MerovciASolis-HerreraCDanieleGDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJ Clin Invest2014124250951424463448
   PubMed Web of Science ®Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• TikkanenIChiltonRJohansenOEPotential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertensionCurr Opin Nephrol Hypertens2016252818626808705
   PubMed Web of Science ®Google Scholar
• LiakosAKaragiannisTAthanasiadouEEfficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysisDiabetes Obes Metab2014161098499324766495
   PubMed Web of Science ®Google Scholar
• VirmaniRBurkeAPFarbAKolodgieFDPathology of the vulnerable plaqueJ Am Coll Cardiol2006478 supplC13C1816631505
   PubMed Web of Science ®Google Scholar
• OjimaAMatsuiTNishinoYNakamuraNYamagishiSEmpagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axisHorm Metab Res201547968669225611208
   PubMed Web of Science ®Google Scholar
• PatilVCPatilHCShahKBVasaniJDShettyPDiastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic functionJ Cardiovasc Dis Res20112421322222135479
   PubMedGoogle Scholar
• RedfieldMMJacobsenSJBurnettJCJrMahoneyDWBaileyKRRodehefferRJBurden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemicJAMA2003289219420212517230
   PubMed Web of Science ®Google Scholar
• BellaJNPalmieriVRomanMJMitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart StudyCirculation2002105161928193311997279
   PubMed Web of Science ®Google Scholar
• ChiltonRTikkanenICannonCPEffects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes Obes Metab201517121180119326343814
   PubMed Web of Science ®Google Scholar
• KodamaSHorikawaCFujiharaKMeta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitusAm J Cardiol201411361058106524462067
   PubMed Web of Science ®Google Scholar
• VlachopoulosCAznaouridisKStefanadisCPrediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysisJ Am Coll Cardiol201055131318132720338492
   PubMed Web of Science ®Google Scholar
• FranklinSSLarsonMGKhanSADoes the relation of blood pressure to coronary heart disease risk change with aging? The Framing-ham Heart StudyCirculation200110391245124911238268
   PubMed Web of Science ®Google Scholar
• MottramPMHaluskaBALeanoRCarlierSCaseCMarwickTHRelation of arterial stiffness to diastolic dysfunction in hypertensive heart diseaseHeart200591121551155616287739
   PubMed Web of Science ®Google Scholar
• LubranoVBalzanSRoles of LOX-1 in microvascular dysfunctionMicrovasc Res201610513214026907636
   PubMed Web of Science ®Google Scholar
• BakrisGLBankAJKassDANeutelJMPrestonRAOparilSAdvanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging processAm J Hypertens20041712 pt 223s30s15607432
   PubMed Web of Science ®Google Scholar
• NeelandIJMcGuireDKChiltonREmpagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitusDiab Vasc Dis Res201613211912626873905
   PubMed Web of Science ®Google Scholar
• PloskerGLCanagliflozin: a review of its use in patients with type 2 diabetes mellitusDrugs201474780782424831734
   PubMed Web of Science ®Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet2013382989694195023850055
   PubMed Web of Science ®Google Scholar
• PloskerGLDapagliflozin: a review of its use in patients with type 2 diabetesDrugs201474182191220925389049
   PubMed Web of Science ®Google Scholar
• BakerWLSmythLRRicheDMBourretEMChamberlinKWWhiteWBEffects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysisJ Am Soc Hypertens201484262275.e26924602971
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
   PubMed Web of Science ®Google Scholar
• GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
   PubMed Web of Science ®Google Scholar
• SpinarJSpinarovaLVitovecJThe TECOS, EXAMINE and SAVOR studies – how do they differ and what are their outcomes?Vnitr Lek20156111976983 In Czech26652787
   PubMedGoogle Scholar
• MozaffarianDBenjaminEJGoASExecutive summary: heart disease and stroke statistics-2016 update: a report from the American Heart AssociationCirculation2016133444745426811276
   PubMed Web of Science ®Google Scholar
• TracquiPBroisatAToczekJMesnierNOhayonJRiouLMapping elasticity moduli of atherosclerotic plaque in situ via atomic force microscopyJ Struct Biol2011174111512321296163
   PubMed Web of Science ®Google Scholar
• PedrigiRMde SilvaRBovensSMMehtaVVPetrettoEKramsRThin-cap fibroatheroma rupture is associated with a fine interplay of shear and wall stressArterioscler Thromb Vasc Biol201434102224223125060797
   PubMed Web of Science ®Google Scholar
• CusiKConsoliADeFronzoRAMetabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitusJ Clin Endocrinol Metab19968111405940678923861
   PubMed Web of Science ®Google Scholar
• CherneyDZPerkinsBASoleymanlouNRenal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitusCirculation2014129558759724334175
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation (HOPE) Study InvestigatorsEffects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study InvestigatorsLancet2000355920025325910675071
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
   PubMed Web of Science ®Google Scholar
• OkadaMMatsumoriAOnoKCyclic stretch upregulates production of interleukin-8 and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in human endothelial cellsArterioscler Thromb Vasc Biol19981868949019633928
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38BMJ199831771607037139732337
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative GroupIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med20083582560257218539916
   PubMed Web of Science ®Google Scholar